Updated data on effective and safe immunizations with live-attenuated vaccines for children after living donor liver transplantation

Masayoshi Shinjo(H), Ken Hoshino, Takao Takahashi, Tetsuo Nakayama

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Although immunizations using live-attenuated vaccines are not recommended for children post-liver transplant due to their theoretical risks, they will inevitably encounter vaccine-preventable viral diseases upon returning to real-life situations. The window of opportunity for vaccination is usually limited prior to transplantation because these children often have unstable disease courses. Also, vaccine immunity does not always persist after transplantation. Methods: Beginning in 2002, subcutaneous immunizations with four individual live-attenuated vaccines (measles, rubella, varicella, and mumps) to pediatric patients following living donor liver transplantation (LDLT) were performed for those who fulfilled the clinical criteria, including humoral and cell-mediated immunity. Written informed consent was collected. We included the study on 70 immunizations for 18 cases that we reported in 2008 (Shinjoh et al., 2008). Results: A total of 196 immunizations were administered to 48 pediatric post-LDLT recipients. Of these, 144 were first immunizations and 52 were repeated immunizations following LDLT. The seroconversion rates at the first dose for measles (AIK-C), rubella (TO-336), varicella (Oka), and mumps (Hoshino) were 100% (36/36), 100% (35/35), 70% (23/33), and 75% (24/32), respectively. Antibody levels did not fall over time in patients immunized with rubella vaccine. Three mild cases of breakthrough varicella were observed. Two cases with transient parotid gland swelling were observed after mumps immunization. Two admissions because of fever at 2-3 weeks after the measles vaccine were reported but the patients had no symptoms of measles. Conclusions: Immunizations using selected live-attenuated vaccines were safe and effective for post-LDLT children who were not severely immunosuppressed. However, with the exception of rubella, repeated immunization may be necessary.

Original languageEnglish
Pages (from-to)701-707
Number of pages7
JournalVaccine
Volume33
Issue number5
DOIs
Publication statusPublished - 2015 Jan 29

Fingerprint

liver transplant
Attenuated Vaccines
Living Donors
live vaccines
Liver Transplantation
Immunization
immunization
Mumps
Chickenpox
Rubella
Measles
vaccines
Vaccines
Transplantation
Rubella Vaccine
Pediatrics
parotid gland
Measles Vaccine
Parotid Gland
seroconversion

Keywords

  • Child
  • Immunization
  • Live-attenuated vaccine
  • Liver transplantation

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Updated data on effective and safe immunizations with live-attenuated vaccines for children after living donor liver transplantation. / Shinjo(H), Masayoshi; Hoshino, Ken; Takahashi, Takao; Nakayama, Tetsuo.

In: Vaccine, Vol. 33, No. 5, 29.01.2015, p. 701-707.

Research output: Contribution to journalArticle

@article{9c7dfa33b03346e182405c46cfaf3a90,
title = "Updated data on effective and safe immunizations with live-attenuated vaccines for children after living donor liver transplantation",
abstract = "Background: Although immunizations using live-attenuated vaccines are not recommended for children post-liver transplant due to their theoretical risks, they will inevitably encounter vaccine-preventable viral diseases upon returning to real-life situations. The window of opportunity for vaccination is usually limited prior to transplantation because these children often have unstable disease courses. Also, vaccine immunity does not always persist after transplantation. Methods: Beginning in 2002, subcutaneous immunizations with four individual live-attenuated vaccines (measles, rubella, varicella, and mumps) to pediatric patients following living donor liver transplantation (LDLT) were performed for those who fulfilled the clinical criteria, including humoral and cell-mediated immunity. Written informed consent was collected. We included the study on 70 immunizations for 18 cases that we reported in 2008 (Shinjoh et al., 2008). Results: A total of 196 immunizations were administered to 48 pediatric post-LDLT recipients. Of these, 144 were first immunizations and 52 were repeated immunizations following LDLT. The seroconversion rates at the first dose for measles (AIK-C), rubella (TO-336), varicella (Oka), and mumps (Hoshino) were 100{\%} (36/36), 100{\%} (35/35), 70{\%} (23/33), and 75{\%} (24/32), respectively. Antibody levels did not fall over time in patients immunized with rubella vaccine. Three mild cases of breakthrough varicella were observed. Two cases with transient parotid gland swelling were observed after mumps immunization. Two admissions because of fever at 2-3 weeks after the measles vaccine were reported but the patients had no symptoms of measles. Conclusions: Immunizations using selected live-attenuated vaccines were safe and effective for post-LDLT children who were not severely immunosuppressed. However, with the exception of rubella, repeated immunization may be necessary.",
keywords = "Child, Immunization, Live-attenuated vaccine, Liver transplantation",
author = "Masayoshi Shinjo(H) and Ken Hoshino and Takao Takahashi and Tetsuo Nakayama",
year = "2015",
month = "1",
day = "29",
doi = "10.1016/j.vaccine.2014.11.052",
language = "English",
volume = "33",
pages = "701--707",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "5",

}

TY - JOUR

T1 - Updated data on effective and safe immunizations with live-attenuated vaccines for children after living donor liver transplantation

AU - Shinjo(H), Masayoshi

AU - Hoshino, Ken

AU - Takahashi, Takao

AU - Nakayama, Tetsuo

PY - 2015/1/29

Y1 - 2015/1/29

N2 - Background: Although immunizations using live-attenuated vaccines are not recommended for children post-liver transplant due to their theoretical risks, they will inevitably encounter vaccine-preventable viral diseases upon returning to real-life situations. The window of opportunity for vaccination is usually limited prior to transplantation because these children often have unstable disease courses. Also, vaccine immunity does not always persist after transplantation. Methods: Beginning in 2002, subcutaneous immunizations with four individual live-attenuated vaccines (measles, rubella, varicella, and mumps) to pediatric patients following living donor liver transplantation (LDLT) were performed for those who fulfilled the clinical criteria, including humoral and cell-mediated immunity. Written informed consent was collected. We included the study on 70 immunizations for 18 cases that we reported in 2008 (Shinjoh et al., 2008). Results: A total of 196 immunizations were administered to 48 pediatric post-LDLT recipients. Of these, 144 were first immunizations and 52 were repeated immunizations following LDLT. The seroconversion rates at the first dose for measles (AIK-C), rubella (TO-336), varicella (Oka), and mumps (Hoshino) were 100% (36/36), 100% (35/35), 70% (23/33), and 75% (24/32), respectively. Antibody levels did not fall over time in patients immunized with rubella vaccine. Three mild cases of breakthrough varicella were observed. Two cases with transient parotid gland swelling were observed after mumps immunization. Two admissions because of fever at 2-3 weeks after the measles vaccine were reported but the patients had no symptoms of measles. Conclusions: Immunizations using selected live-attenuated vaccines were safe and effective for post-LDLT children who were not severely immunosuppressed. However, with the exception of rubella, repeated immunization may be necessary.

AB - Background: Although immunizations using live-attenuated vaccines are not recommended for children post-liver transplant due to their theoretical risks, they will inevitably encounter vaccine-preventable viral diseases upon returning to real-life situations. The window of opportunity for vaccination is usually limited prior to transplantation because these children often have unstable disease courses. Also, vaccine immunity does not always persist after transplantation. Methods: Beginning in 2002, subcutaneous immunizations with four individual live-attenuated vaccines (measles, rubella, varicella, and mumps) to pediatric patients following living donor liver transplantation (LDLT) were performed for those who fulfilled the clinical criteria, including humoral and cell-mediated immunity. Written informed consent was collected. We included the study on 70 immunizations for 18 cases that we reported in 2008 (Shinjoh et al., 2008). Results: A total of 196 immunizations were administered to 48 pediatric post-LDLT recipients. Of these, 144 were first immunizations and 52 were repeated immunizations following LDLT. The seroconversion rates at the first dose for measles (AIK-C), rubella (TO-336), varicella (Oka), and mumps (Hoshino) were 100% (36/36), 100% (35/35), 70% (23/33), and 75% (24/32), respectively. Antibody levels did not fall over time in patients immunized with rubella vaccine. Three mild cases of breakthrough varicella were observed. Two cases with transient parotid gland swelling were observed after mumps immunization. Two admissions because of fever at 2-3 weeks after the measles vaccine were reported but the patients had no symptoms of measles. Conclusions: Immunizations using selected live-attenuated vaccines were safe and effective for post-LDLT children who were not severely immunosuppressed. However, with the exception of rubella, repeated immunization may be necessary.

KW - Child

KW - Immunization

KW - Live-attenuated vaccine

KW - Liver transplantation

UR - http://www.scopus.com/inward/record.url?scp=84921283996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921283996&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2014.11.052

DO - 10.1016/j.vaccine.2014.11.052

M3 - Article

VL - 33

SP - 701

EP - 707

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 5

ER -